Charles River Laboratories International, Inc.
CRL
$166.91
-$2.73-1.61%
NYSE
| 03/29/2025 | 12/28/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -105.76% | -96.51% | -11.96% | -9.95% | -11.59% |
| Total Depreciation and Amortization | 9.13% | 12.17% | 9.32% | 7.80% | 5.49% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 25,284.56% | 16,132.11% | -179.07% | 112.91% | 107.47% |
| Change in Net Operating Assets | 132.55% | 70.38% | 160.15% | 87.65% | 61.71% |
| Cash from Operations | 10.22% | 7.41% | 14.11% | 19.96% | 12.45% |
| Capital Expenditure | 26.70% | 26.86% | 28.42% | 21.68% | 17.19% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 96.21% | 97.19% | -199.20% | -199.20% | 56.64% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 92.01% | 86.68% | 66.43% | 25.37% | 71.41% |
| Cash from Investing | 57.37% | 56.48% | -45.28% | -58.89% | 29.21% |
| Total Debt Issued | 35.30% | 39.32% | 191.72% | 17.28% | -59.47% |
| Total Debt Repaid | -36.87% | -75.39% | -74.39% | -9.23% | 53.92% |
| Issuance of Common Stock | -93.28% | -6.72% | 7.36% | 27.52% | 42.94% |
| Repurchase of Common Stock | -3,094.12% | -393.38% | -393.03% | 23.67% | 38.76% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -442.10% | -273.21% | -409.79% | -321.01% | 75.86% |
| Cash from Financing | -629.96% | -544.20% | 23.27% | 11.52% | -2,286.16% |
| Foreign Exchange rate Adjustments | -89.77% | -317.23% | -14.49% | -131.80% | -109.36% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -182.38% | -282.38% | 250.60% | -1,870.11% | 475.73% |